Low-grade (WHO II) and anaplastic (WHO III) gliomas: differences in morphology and MRI signal intensities

Schäfer, M.; Maurer, Martin; Synowitz, Michael; Wüstefeld, Joost; Marnitz, Tim; Streitparth, Florian; Wiener, Edzard

doi:10.1007/s00330-013-2886-y

Cited by 20 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRI is the modality of choice in the clinical diagnosis, treatment planning, and follow-up of brain tumors. Sufficient differentiation of grade II and III gliomas using conventional MRI remains challenging, due to similar imaging presentations as both grades are able to enhance and both grades may grow necrotic [28]. In agreement with the study of Qi et al (2014) only for necrosis and CE could be found significant correlations, whereas edema and tumor size did not show significant results [1,5].…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

T2 mapping of molecular subtypes of WHO grade II/III gliomas

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: According to the new WHO classification from 2016, molecular profiles have shown to provide reliable information about prognosis and treatment response. The purpose of our study is to evaluate the diagnostic potential of non-invasive quantitative T2 mapping in the detection of IDH1/2 mutation status in grade II-III gliomas. Methods: Retrospective evaluation of MR examinations in 30 patients with histopathological proven WHO-grade II (n = 9) and III (n = 21) astrocytomas (18 IDH-mutated, 12 IDH-wildtype). Consensus annotation by two observers by use of ROI's in quantitative T2-mapping sequences were performed in all patients. T2 relaxation times were measured pixelwise. Results: A significant difference (p = 0,0037) between the central region of IDH-mutated tumors (356,83 ± 114,97 ms) and the IDH-wildtype (199,92 ± 53,13 ms) was found. Furthermore, relaxation times between the central region (322, 62 ± 127,41 ms) and the peripheral region (211,1 ± 74,16 ms) of WHO grade II and III astrocytomas differed significantly (p = 0,0021). The central regions relaxation time of WHO-grade II (227,44 ± 80,09 ms) and III gliomas (322,62 ± 127,41 ms) did not differ significantly (p = 0,2276). The difference between the smallest and the largest T2 value (so called "range") is significantly larger (p = 0,0017) in IDH-mutated tumors (230,89 ± 121,11 ms) than in the IDH-wildtype (96, 33 ± 101,46 ms). Interobserver variability showed no significant differences. Conclusions: Quantitative evaluation of T2-mapping relaxation times shows significant differences regarding the IDHstatus in WHO grade II and III gliomas adding important information regarding the new 2016 World Health Organization (WHO) Classification of tumors of the central nervous system. This to our knowledge is the first study regarding T2 mapping and the IDH1/2 status shows that the mutational status seems to be more important for the appearance on T2 images than the WHO grade.

show abstract

Section: Discussionsupporting

confidence: 84%

“…Furthermore, a significant difference between the central and peripheral tumor regions was found. Although, histopathological tissue examination remains the diagnostic gold standard, T2 mapping is a noninvasive examination and provides additional information about the macroscopic and microscopic composition [28,29].…”

Section: Discussionmentioning

confidence: 99%

T2 mapping of molecular subtypes of WHO grade II/III gliomas

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In previous studies, many morphological criteria were assessed by radiologists for glioma grading with a certain degree of success. 33,34 Riemann et al 35 introduced an MR image scoring guideline based on nine criteria for the grading of noninvasive gliomas. The criteria included cyst formation or necrosis, hemorrhage, degree of contrast enhancement, and other features.…”

Section: Discussionmentioning

confidence: 99%

Radiomics Nomogram Building From Multiparametric MRI to Predict Grade in Patients With Glioma: A Cohort Study

Wang

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Glioma samples were successfully collected from 27 patients with glioma who were undergoing resection surgery at the Department of Neurosurgery, between 2010 and 2013. Tissue samples were diagnosed by pathological section and classified into 12 low-and 15 high-malignancy gliomas, according to the WHO guidelines (29)(30)(31)(32)(33). The tissue samples immediately underwent tissue digestion and cell isolation.…”

Section: Methodsmentioning

confidence: 99%

High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas

Wang

Zhang

Weigao

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Glioma is a type of tumor derived from glial cells, which is associated with a high level of incidence and mortality. At present, the generation of a fast and efficient method to evaluate the malignancy grade of glioma is required. Cancer stem cells (CSCs) are currently attracting attention in oncological studies; therefore, the present study aimed to investigate novel biomarkers of glioma CSCs, in order to provide new criteria for the grading of glioma. The mRNA expression levels of CD133, (sex determining region Y)-box 2, nestin, vascular endothelial growth factor (VEGF) and phosphoinositide-3-kinase (PI3K) were detected in 15 human samples of high-malignancy glioma and 12 human samples of low-malignancy glioma in vitro. The mRNA expression levels of VEGF and PI3K were higher in the high-malignancy group, as compared with in the low-malignancy group. In conclusion, the mRNA expression levels of VEGF and PI3K in glioma CSCs may be considered a novel criteria for the grading of glioma.

show abstract

Low-grade (WHO II) and anaplastic (WHO III) gliomas: differences in morphology and MRI signal intensities

Cited by 20 publications

References 25 publications

T2 mapping of molecular subtypes of WHO grade II/III gliomas

T2 mapping of molecular subtypes of WHO grade II/III gliomas

Radiomics Nomogram Building From Multiparametric MRI to Predict Grade in Patients With Glioma: A Cohort Study

High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas

Contact Info

Product

Resources

About